Unknown OBSERVATIONAL NCT02891213

Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus. (R-PA14098)

Sponsor: CHU de Reims

Updated 7 times since 2017 Last updated: Sep 22, 2016 Started: Nov 30, 2016 Primary completion: Jan 31, 2017 Completion: Oct 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02891213, this observational or N/A phase trial focuses on Lupus Erythematosus and remains ongoing. Sponsored by CHU de Reims, it has been updated 7 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status
Oct 2018 — Jan 2021 [monthly]

Unknown Status

Status: Not Yet Recruiting → Unknown Status
Jun 2018 — Oct 2018 [monthly]

Not Yet Recruiting

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Not Yet Recruiting

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Not Yet Recruiting NA

First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CHU de Reims

Data source: CHU de Reims

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Reims, France